Menu
Search
|

Menu

Close
X

Cipla Ltd CIPL.NS (National Stock Exchange of India)

595.65 INR
+6.00 (+1.02%)
As of Feb 23
chart
Previous Close 589.65
Open 591.80
Volume 1,576,584
3m Avg Volume 1,530,643
Today’s High 605.00
Today’s Low 590.00
52 Week High 663.40
52 Week Low 480.20
Shares Outstanding (mil) 805.00
Market Capitalization (mil) 479,495.31
Forward P/E 41.05
Dividend (Yield %) 2.00 ( 0.34 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.26 Mean rating from 38 analysts

KEY STATS

Revenue (mm, INR)
FY18
115,213
FY17
146,303
FY16
135,949
FY15
113,454
EPS (INR)
FY18
15.280
FY17
12.490
FY16
16.884
FY15
14.645
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
41.05
33.62
Price to Sales (TTM)
vs sector
3.17
8.35
Price to Book (MRQ)
vs sector
--
5.22
Price to Cash Flow (TTM)
vs sector
16.68
25.88
Total Debt to Equity (MRQ)
vs sector
--
15.84
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
--
13.63
Return on Equity (TTM)
vs sector
--
15.39

EXECUTIVE LEADERSHIP

Yusuf Hamied
Non-Executive Chairman of the Board, Since 2016
Salary: --
Bonus: --
Umang Vohra
Global Chief Executive Officer, Managing Director, Additional Director, Since 2016
Salary: Rs16,800,000.00
Bonus: Rs50,000,000.00
Samina Vaziralli
Executive Vice Chairman of the Board, Since 2016
Salary: Rs14,700,000.00
Bonus: Rs11,400,000.00
M. Hamied
Non-Executive Vice Chairman of the Board, Since 2016
Salary: --
Bonus: --
Kedar Upadhye
Global Chief Financial Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Mumbai Central
MUMBAI     400013

Phone: +9122.24826000

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.

SPONSORED STORIES